CFOR · XBRL financial data
CapForce financial statements, every quarter
The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (CFOR's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | Dec 31, 2023 | Jun 5, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 699 | 1,070* | — | 28 | 0* | year only | 0 | 4,000 | 0* | year only | 0 | 50,000 |
| Revenue from contracts with customers | 699 | — | — | — | — | — | — | — | — | — | — | — |
| Cost of goods and services sold | 619 | 1,159* | — | — | — | — | — | — | — | — | — | — |
| Research and development | 1,202 | 329* | — | 23 | 0 | (0)* | — | — | — | year only | 2 | 0 |
| General and administrative | 2,035 | 1,198* | — | 1,569 | 769 | 521* | 513 | 595 | 702 | 1,323* | 798 | 713 |
| Operating income (loss) | (3,566) | (16,957)* | — | (1,547) | (784) | 4,401* | (523) | 3,403 | (702) | 21,850* | (805) | 44,286 |
| Interest expense | 397 | 140* | — | 1 | 3 | 3* | 3 | 2 | 4 | 2* | 1 | 2 |
| Income tax expense (benefit) | — | — | — | — | — | year only | — | 0 | — | year only | — | 1,904 |
| Net income (loss) | (4,063) | (17,042)* | — | (1,576) | 8,931 | 4,350* | (408) | 3,510 | (609) | 21,127* | (711) | 42,471 |
| Earnings per share, basic USD per share | (0.46) | — | — | (1.18) | 1.43 | — | (0.04) | 0.35 | (0.06) | 2.09* | (0.06) | 3.41 |
| Earnings per share, diluted USD per share | (0.46) | — | — | (1.18) | 1.35 | — | (0.04) | 0.34 | (0.06) | 2.07* | (0.06) | 3.38 |
| Weighted average shares, basic thousands of shares | 8,778 | — | — | 1,340 | 5,760 | — | 10,071 | 10,071 | 10,071 | 10,089* | 11,828 | 12,379 |
| Weighted average shares, diluted thousands of shares | 8,778 | — | — | 1,340 | 6,604 | — | 10,071 | 10,168 | 10,071 | 10,203* | 11,828 | 12,489 |
Balance sheet
CSVFiscal quarters (CFOR's year ends in late December)
Cash flows
CSVFiscal quarters (CFOR's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | Dec 31, 2023 | Jun 5, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (4,063) | (17,042)* | — | (1,576) | 8,931 | 4,350* | (408) | 3,510 | (609) | 21,127* | (711) | 42,471 |
| Stock-based compensation | (229) | 98* | — | 368 | 2 | 44* | 82 | 101 | 101 | 58* | 112 | 69* |
| Depreciation and amortization | 349* | 248* | — | 43* | 44* | 45* | 46 | 47* | 48* | 50* | 50 | 52* |
| Net cash from operating activities | (2,928)* | (1,676)* | — | (720)* | (2,833)* | (232)* | (198) | (447)* | (333)* | (205)* | (364) | (618)* |
| Purchases of property and equipment | 102* | 1* | — | — | — | — | — | — | — | year only | — | — |
| Net cash from investing activities | (102)* | (1)* | — | — | — | — | — | — | — | year only | — | — |
| Proceeds from issuing common stock | 30* | 1,853* | — | — | — | — | — | — | — | — | — | — |
| Net cash from financing activities | 28* | 2,098* | — | 621* | 4,298* | (90)* | (90) | 257* | (84)* | 414* | (87) | 688* |
| Net change in cash | (2,949)* | 669* | — | (99)* | 1,465* | (323)* | (198) | (281)* | (417)* | 117* | (453) | 71* |
Compare with peers
SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
- A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| CapForce | 144 | 50,000 | (618)* | 12.4M | 0.2 quarters | 10-QJun 30, 2026 |
| American Shared Hospital Services | 6,511 | 8,430 | 2,236* | 6.7M | — | 10-QJun 30, 2026 |
| Ludwig Enterprises | 18 | not reported | (153) | 167.2M | 1.3 quarters | 10-QMar 31, 2026 |
| Biodesix | 29,996 | 26,861 | (1,562)* | 10.6M | 19.2 quarters | 10-QJun 30, 2026 |
| BillionToOne | 548,628 | 109,448 | 9,136* | not reported | — | 10-QJun 30, 2026 |
| BioNexus Gene Lab | 1,233 | 76 | (422)* | 2.9M | 2.9 quarters | 10-QJun 30, 2026 |
| Aclarion | 16,285 | 25 | (2,657)* | 2.9M | 6.1 quarters | 10-QJun 30, 2026 |
| Advanced Biomed | 386 | year only | (583)* | 1.7M | 0.7 quarters | 10-KJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.